Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert Bissonnette

Showing results (191-200 of 223) with videos related to

Pageof 23
Sort By:
The Journal of Investigative Dermatology|June 29, 2019
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic DermatitisChris Callewaert, Teruaki Nakatsuji, Rob Knight, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Allergy|July 11, 2022
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitisEvgeny Berdyshev, Elena Goleva, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2023
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema CouncilRobert Bissonnette, Eric Simpson, Lawrence F Eichenfield, et al.
Journal of Cutaneous Medicine and Surgery|August 12, 2023
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, et al.
The Journal of Allergy and Clinical Immunology|February 10, 2019
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitisEmma Guttman-Yassky, Ana B Pavel, Lisa Zhou, et al.
Allergy|November 20, 2023
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 studyRobert Bissonnette, Janet DuBois, Paola Facheris, et al.
Journal of the American Academy of Dermatology|February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2025
Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumabElena Goleva, Evgeny Berdyshev, Simion Kreimer, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Pageof 23

Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
The Journal of Investigative Dermatology|June 29, 2019
IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic DermatitisChris Callewaert, Teruaki Nakatsuji, Rob Knight, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Allergy|July 11, 2022
Dupilumab significantly improves skin barrier function in patients with moderate-to-severe atopic dermatitisEvgeny Berdyshev, Elena Goleva, Robert Bissonnette, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|November 9, 2023
The vIGA-AD scale for atopic dermatitis: Uptake in the past 5 years and position of the International Eczema CouncilRobert Bissonnette, Eric Simpson, Lawrence F Eichenfield, et al.
Journal of Cutaneous Medicine and Surgery|August 12, 2023
Baseline Characteristics of Canadian Patients in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)Melinda J Gooderham, Robert Bissonnette, Sunil Kalia, et al.
The Journal of Allergy and Clinical Immunology|February 10, 2019
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitisEmma Guttman-Yassky, Ana B Pavel, Lisa Zhou, et al.
Allergy|November 20, 2023
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 studyRobert Bissonnette, Janet DuBois, Paola Facheris, et al.
Journal of the American Academy of Dermatology|February 18, 2021
Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5)Eric L Simpson, Seth Forman, Jonathan I Silverberg, et al.
The Journal of Allergy and Clinical Immunology|January 25, 2025
Longitudinal integrated proteomic and metabolomic skin changes in patients with atopic dermatitis treated with dupilumabElena Goleva, Evgeny Berdyshev, Simion Kreimer, et al.
The New England Journal of Medicine|December 8, 2021
Phase 3 Trials of Tapinarof Cream for Plaque PsoriasisMark G Lebwohl, Linda Stein Gold, Bruce Strober, et al.
Pageof 23